Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Foghorn Therapeutics ( (FHTX) ) is now available.
On December 3, 2025, Foghorn Therapeutics appointed Jeff Sacher as Treasurer and interim CFO, while continuing its search for a permanent CFO. Mr. Sacher, a seasoned professional with extensive experience in biotechnology and investment banking, will provide interim CFO services through Danforth Advisors, a consultancy firm specializing in life sciences companies. This appointment is expected to bring strategic financial expertise to Foghorn Therapeutics during this transitional period.
The most recent analyst rating on (FHTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.
Spark’s Take on FHTX Stock
According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral.
Foghorn Therapeutics’ overall stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and high leverage. The technical analysis provides a slightly better outlook with some positive momentum indicators, but the valuation remains unattractive due to negative earnings. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on FHTX stock, click here.
More about Foghorn Therapeutics
Foghorn Therapeutics Inc. operates in the biotechnology industry, focusing on developing innovative therapies and solutions for various medical conditions.
Average Trading Volume: 205,222
Technical Sentiment Signal: Sell
Current Market Cap: $242.6M
For detailed information about FHTX stock, go to TipRanks’ Stock Analysis page.